E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nervous System Diseases [C10] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | HLT |
E.1.2 | Classification code | 10036017 |
E.1.2 | Term | Poliomyelitis viral infections |
E.1.2 | System Organ Class | 10021881 - Infections and infestations |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
· To determine the effect of V-073 and placebo treatment on poliovirus serotype 1 excretion in the stool after administration of mOPV1 as determined by virus culture;
· To evaluate the safety and tolerability of multiple oral doses of V-073 administered to healthy volunteers; |
|
E.2.2 | Secondary objectives of the trial |
· To evaluate the pharmacokinetics profile of V-073 after administration of multiple oral doses;
· To determine the duration of poliovirus excretion in V-073 and placebo treated subjects;
· To determine the levels of poliovirus excretion over time with V-073 or placebo treatment;
· To compare the effectiveness of V-073 on poliovirus excretion when administered afterconsumption of a standard and high fat meal;
· To determine the initial and post-V-073 treatment susceptibility of excreted poliovirus to V-073;
· To determine the poliovirus-specific serum IgA and serum neutralizing (SN) antibody levels before and after treatment with V-073. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Be a healthy, non-smoking male or female of any race, having received prior vaccination with inactivated polio vaccine, and at
least 18 years old and no more than 50 years old, inclusively;
2. Have a body mass index (BMI) within the range of >18.5 and <30 unless
approved by the Sponsor and Investigator;
3. Be healthy as determined by pre study medical history, physical examination,
12 lead ECG and clinical laboratory evaluations;
4. Be positive for total serum IgA (indicative of immunocompetence);
5. Be negative for poliovirus-specific serum IgA (serotype 1) (indicative of no prior exposure to live poliovirus);
6. Have no history of immunodeficiency;
7. Have regular bowel movements, at least once per day (self reported);
8. Be informed of the nature of the study and provide written informed consent;
9. Be legally competent and able to communicate effectively with study personnel. |
|
E.4 | Principal exclusion criteria |
1. A history of natural or OPV-derived poliovirus infection;
2. Female subjects who are pregnant, attempting to become pregnant or lactating;
3. Any disease or condition that might compromise the cardiovascular,
hematological, renal, hepatic, pulmonary (including chronic asthma), endocrine
(e.g., diabetes), central nervous, or gastrointestinal (including a gastric or
duodenal ulcer) systems;
4. The presence of clinically significant abnormal laboratory values in the opinion
of the Investigator or Sponsor;
5. A history of alcoholism or drug addiction within the past 2 years, recent use of
any recreational drugs, or positive results from a urine screen for substances of
abuse and alcohol at screening and admission;
6. A history of serious mental illness, that includes but is not limited to
schizophrenia, bipolar disorder, or severe depression requiring hospitalization or
pharmacological intervention;
7. Is a member of a household in which another member is known to be
immunodeficient or is actively being treated for a malignancy, autoimmune
disease or transplant;
8. A history of difficulty donating blood or inadequate venous access;
9. The donation of blood or plasma within 30 days prior to receiving study drug;
10. Lactose intolerant;
11. A positive hepatitis screen that tests for both hepatitis B surface antigen (HBsAg)
and antibody to hepatitis C (HCV);
12. A positive test result for HIV antibody by enzyme immunoassay which is
confirmed by Western immunoblot;
13. Receipt of an investigational drug or product, or participation in a drug study
within a period of 30 days prior to receiving study drug (for investigational drugs
with an elimination half-life greater than 10 days, this will be extended to 60
days);
14. Use of any drug or medication known to suppress/inhibit the immune system
(e.g., steroids such as prednisone);
15. Use of a drug therapy known to induce or inhibit hepatic drug metabolism within
30 days prior to receiving study drug or during the study.
16. Use of any prescription or over-the-counter (OTC) drug therapy, excluding
paracetamol and including herbal, homeopathic, vitamins, minerals and
nutritional supplements, unapproved by the Sponsor, within 2 weeks prior to
receiving the study drug (for drugs with an elimination half-life greater than 10
days, this will be extended to 60 days).
17. Use of grapefruits and grapefruit-containing juices within 1 week prior to dosing.
18. Unable to follow the restrictions outlined in the protocol ; or judgment by the PI that the subject should not participate in the study; |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Pharmacokinetics:
• The primary pharmacokinetic measure will be the single and multiple dose plasma pharmacokinetics of V-073
Pharmacodynamics:
• Stool samples will be assessed for virus both qualitatively and quantitatively in a virusinduced cytopathic effect cell culture assay.
• Stool samples may be assessed for virus qualitatively using poliovirus specific RT-PCR methodology. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Pharmacokinetics:
• The primary pharmacokinetic measure will be the single and multiple dose plasma pharmacokinetics of V-073;
• Pharmacokinetic parameters for Day 3 and Day 16 QD dosing will include Cmax, tmax, C24,AUC(0-tau),;
• Cmin (trough) levels of V-073 will be determined by analyzing plasma samples collected prior to the morning dose on Days 4-16, and 24h after the last dose.
Pharmacodynamics:
The resulting virology data will be analyzed for the following endpoints
- Time to virus excretion negativity for chloroform extracted samples.
-Time to virus excretion negativity for non-chloroform extracted samples.
-Daily % subjects virus excretion negative for all sample collection days.
|
|
E.5.2 | Secondary end point(s) |
Drug Susceptibility Group 1 to 4, Group 7 and 8:
Virus from each subject's virus culture positive chloroform-extracted stool sample on Day 3 (or Day 2 if Day 3 sample is not available; pretreatment) and their last virus culture positive stool sample will be assessed for susceptibility to V-073 in a cell culture virus-induced cytopathic effect assay (EC50 determination). Virus samples with reduced drug susceptibility (defined as a
>20-fold increase in EC50 value relative to the corresponding Day 3 [pretreatment] susceptibility) will be sequenced across the VP3 and VP1 protein coding regions to determine the genetic basis for reduced drug susceptibility.
Safety:
Safety and tolerability will be assessed by monitoring adverse
experiences, measuring vital signs, electrocardiograms (ECGs),
assessment of clinical laboratory determinations from blood samples, and performance of physical examinations
Group 5 and 6:
Drug Susceptibility:
Virus from each subject’s virus culture positive chloroform-extracted stool sample on Day 1 (or Day 0 if Day 1 sample is not available; pretreatment) and their last virus culture positive stool sample will be assessed for susceptibility to V-073 in a cell culture virus-induced cytopathic effect assay (EC50 determination). Virus samples with reduced drug susceptibility (defined as a
>20-fold increase in EC50 value relative to the corresponding Day 1 [pretreatment] susceptibility) will be sequenced across the VP3 and VP1 protein coding regions to determine the genetic basis for reduced drug susceptibility.
Safety:
Safety and tolerability will be assessed by monitoring adverse experiences, measuring vital signs, electrocardiograms (ECGs), assessment of clinical laboratory determinations from blood samples, and performance of physical examinations |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Drug Susceptibility:
Group 1 to 4, Group 7 and 8
Day 3 (or Day 2 if Day 3 sample is not available; pretreatment) and their
last virus culture positive stool
Safety:
Day 0 to Day 45
Group 5 and 6:
Drug Susceptibility:
Day 1 (or Day 0 if Day 1 sample is not available; pretreatment) and their last virus culture positive stool
Safety:
Day 0 to Day 43 |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 10 |
E.8.9.1 | In the Member State concerned days | 0 |